1887

Abstract

The rapidly increasing number of multidrug-resistant tuberculosis (MDR-TB) cases worldwide underlines the necessity for the rational use of key second-line drugs such as kanamycin. In this study, we determined the prevalence of, and risk factors associated with, kanamycin-resistant tuberculosis (TB) in 309 Hospital, Beijing, China, with the aim of providing information for better case management in order to minimize further development of extensively drug-resistant TB (XDR-TB). Drug susceptibility testing results and clinical data were retrospectively analysed for hospitalized TB patients for whom such data were available in 309 Hospital for the period 1997–2009. Univariate and multivariate analyses were used to determine the risk factors associated with kanamycin-resistant TB. During 1997–2009, 553 (14.4 %) of 3843 tested isolates from hospitalized TB patients were kanamycin-resistant. The increasing trend of resistance to kanamycin was reversed since 2000. The independent risk factors associated with kanamycin-resistant TB included living in urban areas [adjusted odds ratio (OR) = 1.89], being retreated for repeat cases (adjusted OR = 1.60), being smear-positive for acid-fast bacilli at admission to the hospital (adjusted OR = 1.39), having ofloxacin-resistant (adjusted OR = 1.61) or para-aminosalicylic acid-resistant TB (adjusted OR = 1.47), having MDR-TB (adjusted OR = 5.10), having MDR-TB plus ofloxacin resistance (adjusted OR = 4.27) and having poly-resistant TB (adjusted OR = 3.94). The remaining rate of kanamycin resistance is still high despite the reversal of the increasing trend during the past decade. Surveillance of kanamycin resistance, especially among high-risk populations, should be continued to closely monitor trends so that appropriate action can be taken.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.042655-0
2012-07-01
2020-10-26
Loading full text...

Full text loading...

/deliver/fulltext/jmm/61/7/960.html?itemId=/content/journal/jmm/10.1099/jmm.0.042655-0&mimeType=html&fmt=ahah

References

  1. Abubakar I., Moore J., Drobniewski F., Kruijshaar M., Brown T., Yates M., Anderson C., Smith E. G., Magee J. other authors 2009; Extensively drug-resistant tuberculosis in the UK: 1995 to 2007. Thorax 64:512–515 [CrossRef][PubMed]
    [Google Scholar]
  2. CDC 2006; Notice to readers: revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 55:1176
    [Google Scholar]
  3. Chan E. D., Iseman M. D. 2008; Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis 21:587–595 [CrossRef][PubMed]
    [Google Scholar]
  4. Chiang C. Y., Centis R., Migliori G. B. 2010; Drug-resistant tuberculosis: past, present, future. Respirology 15:413–432 [CrossRef][PubMed]
    [Google Scholar]
  5. China Tuberculosis Control Collaboration 2004; The effect of tuberculosis control in China. Lancet 364:417–422 [CrossRef][PubMed]
    [Google Scholar]
  6. Crofton J., Chaulet P., Maher D. 1997 Guidelines for the Management of Drug-Resistant Tuberculosis, Rev 1. WHO/TB/96.210. Geneva: World Health Organization
  7. Dye C., Espinal M. A., Watt C. J., Mbiaga C., Williams B. G. 2002; Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 185:1197–1202 [CrossRef][PubMed]
    [Google Scholar]
  8. Eisenach K. D., Cave M. D., Bates J. H., Crawford J. T. 1990; Polymerase chain reaction amplification of a repetitive DNA sequence specific for Mycobacterium tuberculosis. J Infect Dis 161:977–981 [CrossRef][PubMed]
    [Google Scholar]
  9. Espinal M. A., Laszlo A., Simonsen L., Boulahbal F., Kim S. J., Reniero A., Hoffner S., Rieder H. L., Binkin N. other authors 2001; Global trends in resistance to antituberculosis drugs. N Engl J Med 344:1294–1303 [CrossRef][PubMed]
    [Google Scholar]
  10. Huang T. S., Kunin C. M., Shin-Jung Lee S., Chen Y. S., Tu H. Z., Liu Y. C. 2005; Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995–2003. J Antimicrob Chemother 56:1058–1062 [CrossRef][PubMed]
    [Google Scholar]
  11. Huong N. T., Lan N. T., Cobelens F. G., Duong B. D., Co N. V., Bosman M. C., Kim S. J., van Soolingen D., Borgdorff M. W. 2006; Antituberculosis drug resistance in the south of Vietnam: prevalence and trends. J Infect Dis 194:1226–1232 [CrossRef][PubMed]
    [Google Scholar]
  12. Kliiman K., Altraja A. 2009; Predictors of extensively drug-resistant pulmonary tuberculosis. Ann Intern Med 150:766–775[PubMed] [CrossRef]
    [Google Scholar]
  13. Liu C. H., Li L., Chen Z., Wang Q., Hu Y. L., Zhu B., Woo P. C. 2011a; Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS ONE 6:e19399 [CrossRef][PubMed]
    [Google Scholar]
  14. Liu C. H., Yang N., Wang Q., Hu Y. L., Li L., Zhang G. Y., Zhu B. 2011b; Risk factors associated with fluoroquinolone-resistant tuberculosis in a Beijing tuberculosis referral hospital. Respirology 16:918–925 [CrossRef][PubMed]
    [Google Scholar]
  15. Migliori G. B., Lange C., Centis R., Sotgiu G., Mütterlein R., Hoffmann H., Kliiman K., De Iaco G., Lauria F. N. other authors 2008; Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 31:1155–1159 [CrossRef][PubMed]
    [Google Scholar]
  16. Paramasivan C. N., Rehman F., Wares F., Sundar Mohan N., Sundar S., Devi S., Narayanan P. R. 2010; First- and second-line drug resistance patterns among previously treated tuberculosis patients in India. Int J Tuberc Lung Dis 14:243–246[PubMed]
    [Google Scholar]
  17. Prammananan T., Arjratanakool W., Chaiprasert A., Tingtoy N., Leechawengwong M., Asawapokee N., Leelarasamee A., Dhiraputra C. 2005; Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis 9:216–219[PubMed]
    [Google Scholar]
  18. Shah N. S., Pratt R., Armstrong L., Robison V., Castro K. G., Cegielski J. P. 2008; Extensively drug-resistant tuberculosis in the United States, 1993–2007. JAMA 300:2153–2160 [CrossRef][PubMed]
    [Google Scholar]
  19. Suárez-García I., Rodríguez-Blanco A., Vidal-Pérez J. L., García-Viejo M. A., Jaras-Hernández M. J., López O., Noguerado-Asensio A. 2009; Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain. Eur J Clin Microbiol Infect Dis 28:325–330 [CrossRef][PubMed]
    [Google Scholar]
  20. Vashakidze L., Salakaia A., Shubladze N., Cynamon M., Barbakadze K., Kikvidze M., Papitashvili L., Nonikashvili M., Solomonia N. other authors 2009; Prevalence and risk factors for drug resistance among hospitalized tuberculosis patients in Georgia. Int J Tuberc Lung Dis 13:1148–1153[PubMed]
    [Google Scholar]
  21. Via L. E., Cho S. N., Hwang S., Bang H., Park S. K., Kang H. S., Jeon D., Min S. Y., Oh T. other authors 2010; Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean patients with drug-resistant tuberculosis. J Clin Microbiol 48:402–411 [CrossRef][PubMed]
    [Google Scholar]
  22. Wang L., Liu J., Chin D. P. 2007; Progress in tuberculosis control and the evolving public-health system in China. Lancet 369:691–696 [CrossRef][PubMed]
    [Google Scholar]
  23. Wang D., Yang C., Kuang T., Lei H., Meng X., Tong A., He J., Jiang Y., Guo F., Dong M. 2010; Prevalence of multidrug and extensively drug-resistant tuberculosis in Beijing, China: a hospital-based retrospective study. Jpn J Infect Dis 63:368–371[PubMed]
    [Google Scholar]
  24. WHO 2000 Anti-tuberculosis Drug Resistance in the World. Report no. 2: Prevalence and Trends. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance WHO/CDS/TB/2000.278. Geneva, Switzerland: World Health Organization. Available at http://whqlibdoc.who.int/hq/2000/WHO_CDS_TB_2000.278_intro.pdf
    [Google Scholar]
  25. WHO 2003 Treatment of Tuberculosis: Guidelines for National Programmes 3rd edn. WHO/CDS/TB/2003.313. Geneva, Switzerland: World Health Organization. Available at http://whqlibdoc.who.int/hq/2003/who_cds_tb_2003.313_eng.pdf
    [Google Scholar]
  26. WHO 2006 Guidelines for the Programmatic Management of Drug-resistant Tuberculosis WHO/HTM/TB/2006.361. Geneva, Switzerland: World Health Organization. Available at http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf
    [Google Scholar]
  27. WHO 2010a Global Tuberculosis Control. WHO Report 2010 WHO/HTM/TB/2010.7. Geneva, Switzerland: World Health Organization. Available at http://whqlibdoc.who.int/publications/2010/9789241564069_eng.pdf
    [Google Scholar]
  28. WHO 2010b Multidrug and Extensively Drug-resistant TB (M/XDR-TB). 2010 Global Report on Surveillance and Response WHO/HTM/TB/2010.3. Geneva, Switzerland: World Health Organization. Available at http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf
    [Google Scholar]
  29. Xianyi C., Fengzeng Z., Hongjin D., Liya W., Lixia W., Xin D., Chin D. P. 2002; The DOTS strategy in China: results and lessons after 10 years. Bull World Health Organ 80:430–436[PubMed]
    [Google Scholar]
  30. Xu P., Li X., Zhao M., Gui X., DeRiemer K., Gagneux S., Mei J., Gao Q. 2009; Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob Agents Chemother 53:3170–3172 [CrossRef][PubMed]
    [Google Scholar]
  31. Zhao M., Li X., Xu P., Shen X., Gui X., Wang L., Deriemer K., Mei J., Gao Q. 2009; Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS ONE 4:e4370 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.042655-0
Loading
/content/journal/jmm/10.1099/jmm.0.042655-0
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error